-
The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
University of Chicago, Chicago, Illinois, USA.
The authors set out to critically review the current data on the efficacy of oral 5-aminosalicylic acid (5-ASA) agents for active ulcerative colitis (UC). Thirty-one studies were identified; 19 met entry criteria. Three trials with mesalamine showed statistical significance versus placebo; those with olsalazine or balsalazide did not. No agent was statistically different from sulfasalazine. In 2 of 3 trials of balsalazide versus mesalamine, results for defined primary and secondary endpoints failed to demonstrate statistically significant differences. Studies suggest that mesalamine is superior to placebo for treating active UC. Five-ASA products appear to be as effective as sulfasalazine, but available data do not suggest a difference in efficacy between any of the 5-ASA preparations.
PMID: 14668693 [PubMed - indexed for MEDLINE]
-
Cited by 1 PubMed Central article
Patient Drug Information
-
Sulfasalazine (Azulfidine® , Azulfidine® EN-tabs® )
Sulfasalazine is used to treat bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain in patients with ulcerative colitis, a condition in which the bowel is inflamed. Sulfasalazine delayed-re...
-
Mesalamine (Asacol® , Canasa® , Pentasa® , ...)
Mesalamine is used to treat ulcerative colitis (a condition in which part or all of the lining of the colon [large intestine] is swollen or worn away). Mesalamine delayed-release tablets and controlled-release capsules m...
-
Olsalazine (Dipentum® )
Olsalazine, an anti-inflammatory medicine, is used to treat ulcerative colitis, a condition in which the bowel is inflamed. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdo...
- »
See all 4 drug reports
...